Combination therapy for advanced bile duct cancer with an FGFR2 change
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a diagnosis of biliary tract cancer that cannot be removed with surgery or has spread to other parts of the body.
- Your tumor must have a specific genetic change in the FGFR2 gene, as shown by a lab test.
- You may have had one prior cycle of certain chemotherapy or immunotherapy drugs (like gemcitabine/cisplatin with or without durvalumab or pembrolizumab) before starting this trial.
- You must be able to take oral medications and have a life expectancy of more than 4 months.
- You must not have brain metastases or spinal cord compression, an active autoimmune disease, or have had an organ or stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This trial tests a combination of two drugs, pemigatinib and durvalumab, for people whose advanced bile duct or gallbladder cancer has already been treated once. It aims to see if the combination can shrink tumors or slow their growth.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new Metastatic Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.